United Therapeutics Corporation (NASDAQ: UTHR) saw its stock price surge 5.43% in Wednesday's pre-market trading session following the release of its impressive first-quarter 2025 financial results. The biotechnology company, focused on developing treatments for chronic lung diseases and other life-threatening conditions, reported significant growth in revenue and earnings that surpassed analysts' expectations.
For the quarter ended March 31, 2025, United Therapeutics reported total revenues of $794.4 million, representing a substantial 17% increase from $677.7 million in the same period last year. This figure notably exceeded the consensus analyst estimate of $729.8 million. The company's earnings per share (EPS) also impressed, coming in at $6.63, up from $6.17 in the prior-year quarter and beating the analyst forecast of $6.31.
The robust financial performance was primarily driven by strong sales growth in the company's Tyvaso product line. Total Tyvaso revenues, including both Tyvaso DPI and nebulized Tyvaso, surged to $466.3 million, marking a 25% increase from $372.5 million in Q1 2024. Tyvaso DPI, in particular, saw remarkable growth, with sales reaching $302.5 million compared to $227.5 million in the previous year.
Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, expressed optimism about the company's future, stating, "2025 is off to a tremendous start as we reported yet another quarter of record revenue." She highlighted upcoming milestones, including the readout of the TETON 2 clinical trial in idiopathic pulmonary fibrosis and the planned commencement of the UKidney first-in-human clinical study. Additionally, the company is advancing its efforts to create an unlimited supply of transplantable organ alternatives, with anticipated filings of investigational new drug applications for its UHeart and UThymoKidney products.
The market's positive reaction to United Therapeutics' Q1 results and future outlook underscores investor confidence in the company's growth trajectory and innovative pipeline. As the company continues to expand its reach in the pulmonary hypertension market and advance its organ manufacturing initiatives, it remains well-positioned for sustained growth in the biotechnology sector.